CORT (Corcept Therapeutics) Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Revenue: $256 million, a 32% increase year-over-year.

Korlym and Authorized Generic Revenue: $208.6 million.

Lifyorli Revenue: $47.6 million in its first quarter of availability.

Net Income: $43 million, up from $35 million in Q2 2025.

Cash and Investments: $545 million as of June 30, 2026.

Updated Revenue Guidance: Increased to $1.1 billion - $1.2 billion for 2026.

2Strategic Updates and Business Highlights

Cushing's Syndrome Business: Record new prescriptions and prescribers; increased awareness of hypercortisolism is driving growth. The company anticipates annual revenue from this segment to reach at least $2 billion by the end of the decade.

Lifyorli Launch: Strong uptake in the oncology market, with over 1,300 patients started on treatment and more than 1,000 unique prescribers. The drug is expected to become a new standard of care for platinum-resistant ovarian cancer.

Clinical Trials: Positive results from the Catalyst and Momentum trials are enhancing physician awareness and treatment adoption. Upcoming trials (BELLA, STELLA, TRIDENT) aim to broaden the application of GR antagonism in oncology.

3Forward Guidance and Outlook

The company expects continued growth in both the endocrinology and oncology segments, driven by the increasing recognition of hypercortisolism and the successful launch of Lifyorli.

Anticipation of relacorilant's approval, with a PDUFA date set for December 17, 2026, is expected to further accelerate growth in the Cushing's syndrome market.

4Bad News, Challenges, or Points of Concern

Regulatory Setbacks: The company faced disappointment with a complete response letter from the FDA regarding relacorilant, which required additional data for its NDA resubmission.

Market Competition: While Lifyorli is gaining traction, the competitive landscape in oncology remains a concern, especially as other treatments may emerge.

Patient Treatment Duration: There is uncertainty regarding the duration of therapy for Lifyorli, as it is still early in the product's lifecycle.

5Notable Q&A Insights

Patient Metrics for Lifyorli: The company reported 1,300 patients initiated on therapy, with a steady pace of new patient additions. The duration of therapy is still being assessed.

Revenue Dynamics: The growth in Korlym revenue was attributed to servicing existing patients rather than clearing backlog from the pharmacy transition.

Inventory Management: Minimal inventory dynamics were noted, with most sales occurring directly to patients through specialty pharmacies. Overall, Corcept Therapeutics is experiencing significant growth driven by its Cushing's syndrome and oncology products, but faces challenges related to regulatory approvals and competitive pressures. The company remains optimistic about its future prospects, particularly with the anticipated approval of relacorilant.